Crowley,John

Institution: University of Arkansas for Medical Sciences, USA

Research Interests: Patients, Survival, Calcium, Arm, Cytogenetic, Cytogenetic Abnormalities, Randomization, Thalidomide, Time, Treatment, Psoriasis, Relapse, Retreatment, Cytostatic Agents, Cytotoxic Agents, Arms, Biology, C-reactive Protein, Data Pooling, Dehydrogenase

Information and abstracts for author publications
Published Date	Impact	Publication
05/17/2010	18.4	Journal of clinical oncology : official journal of the American Society of Clinical Oncology Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.	Abstract
12/06/2010	7.7	Clinical cancer research : an official journal of the American Association for Cancer Research Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.	Abstract
01/28/2011	3.7	The British journal of dermatology Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.	Abstract
12/14/2010	2.6	Annals of hematology Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.	Abstract
11/05/2012	2.5	Current oncology reports The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trials.	Abstract
03/25/2013	2.4	Clinical trials (London, England) Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.	Abstract

Grants Recieved by this author
Budget Start	Budget End	Grant Type	Project Cost	Project Title
9/26/2012	8/31/2014	NIH U54: Specialized Center--Cooperative Agreements	$361,209	Biostatistics Core
1/01/2008	12/31/2011	NIH U10: Cooperative Clinical Research--Cooperative Agreements	$18,649,803	SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER

Related JoVE Videos